Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
July 18, 2018 07:29 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of...
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts - - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...